Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SCGB2A1



This biomarker is also known as:
  • mammaglobin-B,
  • Secretoglobin family 2A member 1,
  • MGC71973,
  • Lacryglobin,
  • O75556,
  • lacryglobin,
  • MGB2,
  • mammaglobin-2,
  • LIPHC,
  • mammaglobin 2,
  • secretoglobin, family 2A, member 1,
  • lipophilin-C,
  • UGB3,
  • Mammaglobin-2,
  • lipophilin C,
  • Lipophilin-C,
  • mammaglobin B,
  • LPHC,

View in BioMuta


SCGB2A1, also known as MGB2 or mammaglobin B, encodes a small secreted protein from the secretoglobin family, part of the uterglobin superfamily. SCGB2A1 is normally expressed in the thymus, trachea, kidney, steroid responsive tissues (prostate, testis, uterus, breast and ovary) and salivary gland.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


SCGB2A1, also known as MGB2 or mammaglobin B, is highly homologous to mammaglobin A (MGB1), which is overexpressed in breast cancer. SCGB2A1 has also been found to be overexpressed in primary breast cancers. Recently SCGB2A1 was found to be a top differentially expressed gene in ovarian cancer.

Performance Comment

SCGB2A1 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. SCGB2A1 was not in the group of 13 selected for further validation.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.